Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
RetinopathyRetinal Vein OcclusionDiabetic RetinopathyMacular Degeneration
Interventions
COMBINATION_PRODUCT

Fluorescein sodium and Zeiss FF450 fundus camera

Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants

COMBINATION_PRODUCT

MB-102 and Zeiss FF450 fundus camera

MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants

COMBINATION_PRODUCT

Fluorescein sodium and commercially available optical angiography imaging system

Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants

COMBINATION_PRODUCT

MB-102 and commercially available optical angiography imaging system

Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants

Trial Locations (1)

48105

University of Michigan Kellogg Eye Center, Ann Arbor

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MediBeacon

INDUSTRY